INSIGHTS FROM THE WORLD’S LEADING EMPLOYERS AND TELADOC HEALTH Solving the GLP-1 Conundrum — Experts and Insiders Weigh In
In the past year, many employers saw increases in pharmacy costs because of a popular class of medication — glucagon-like peptide-1 (GLP-1). Used to treat diabetes for years, changing clinical guidelines and increased demand has employers evaluating how to make these medications accessible for clinically appropriate weight loss. Benefit leaders know these are not a silver bullet, and the cost can upend the most carefully planned budgets. So, how do they ensure GLP-1 medications are prescribed and managed in the most cost-effective way while helping employees achieve their personal health goals? Recently, Employer Health Innovation Roundtable (EHIR) , the leading organization for supporting the largest and most progressive employers in evaluating the latest health and wellness benefits, gathered some of the top innovators in chronic condition management. Innovators, including Teladoc Health ® , contributed to a research report and panel discussion on the topic of diabetes, weight management and the impact of GLP-1 medications.
KEY INSIGHTS
A 2023 survey of EHIR members offered their approach to benefits and medications for cardiometabolic conditions.
60 %
expect utilization of GLP-1 medications to increase in the next 3 years 1 94 % cover GLP-1 medications with 56% covering them for diabetes and weight loss 1 95 % considering adding one or more solutions for prediabetes, diabetes and/or weight management in 18 months (74% have at least one today) 1
144
© Teladoc Health, Inc. All rights reserved.
Made with FlippingBook - Online Brochure Maker